Chipscreen NewWay Biosciences

Chipscreen NewWay Biosciences is a clinical-stage biotechnology company and a subsidiary of Shenzhen Chipscreen Biosciences, specializing in the development of innovative large-molecule therapeutics. The company focuses on oncology and autoimmune diseases, utilizing its proprietary platform to design bispecific antibodies and other biologics. Its lead program, NWY001, is a bispecific antibody targeting PD-L1 and CD47, designed to enhance anti-tumor immune responses while minimizing off-target effects. Based in Chengdu, China, NewWay Biosciences bridges the gap between small-molecule discovery and advanced biological treatments within the Chipscreen portfolio. The company's pipeline includes several early-stage programs aimed at addressing unmet medical needs through novel mechanisms of action. By leveraging the established infrastructure of its parent company, NewWay is positioned to accelerate the clinical translation of complex biological drugs.